nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

31.03.2020 | Brief Report

Evaluation of Xpert MTB/RIF Ultra assay for rapid diagnosis of pulmonary and extra-pulmonary tuberculosis in an Italian center

verfasst von: Melissa Menichini, Nicoletta Lari, Antonella Lupetti, Laura Rindi

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Excerpt

Tuberculosis (TB) is a major infectious disease worldwide. In 2018, the World Health Organization (WHO) estimated 1.3 million deaths and 10.0 million new cases [1]. Rapid detection of Mycobacterium tuberculosis and determination of resistance, based on nucleic acid amplification techniques carried out directly on clinical samples, are essential for early diagnosis and treatment [2, 3]. Since 2010, the WHO recommended the use of Xpert MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, CA, USA), which could simultaneously detect MTBC and RIF resistance conferred by the rpoB gene mutations within 2 h [4‐7]. Recently, the new version Xpert MTB/RIF Ultra (Ultra) has been developed in order to overcome some limitations of the Xpert assay [8]. The aim of the present study was to evaluate the performance of the Ultra assay for pulmonary and extra-pulmonary samples in a region of Italy with low TB incidence. …

WHO (2019) Global tuberculosis report, 2019. http://who.int/tb/publications/global_report/en. Accessed 29 Jan 2020

Forbes BA, Hall GS, Miller MB, Novak SM, Rowlinson M-C, Salfinger M, Somoskövi A, Warshauer DM, Wilson ML (2018) Practice guidelines for clinical microbiology laboratories: mycobacteria. Clin Microbiol Rev 31(2):e00038–e00017CrossRef

Centers for Disease Control and Prevention (CDC) (2009) Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 58:7–10

Boehme C, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD (2010) Rapid molecular detection of tuberculosis and rifampicin resistance. N Engl J Med 363:1005–1015CrossRef

Theron G, Peter J, Calligaro G, Meldau R, Hanrahan C, Khalfey H, Matinyenya B, Muchinga T, Smith L, Pandie S, Lenders L, Patel V, Mayosi BM, Dheda K (2014) Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep 4:5658CrossRef

Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, Dendukuri N, Mandalakas AM (2015) Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med 3:451–461CrossRef

Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, Bekker LG, Wood R (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8(7):e1001067CrossRef

Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D (2017) The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8:e00812–e00817CrossRef

Clinical and Laboratory Standards Institute (2011) Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. 2nd ed. Wayne: CLSI; Approved standard. CLSI document M24-A2

10.

Cepheid (2017) Xpert MTB/RIF ULTRA assay (package insert). Sunnyvale

11.

Rindi L, Garzelli C (2016) Increase in non-tuberculous mycobacteria isolated from humans in Tuscany, Italy, from 2004 to 2014. BMC Infect Dis 16:44CrossRef

12.

Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Peres RL, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM, study team (2018) Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18:76–84CrossRef

13.

Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K (2019) Added value of Xpert MTB/RIF Ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. J Clin Microbiol 57(2):e01717–e01718PubMedPubMedCentral

14.

Osei Sekyere J, Maphalala N, Malinga LA, Mbelle NM, Maningi NE (2019) A comparative evaluation of the new Genexpert MTB/RIF Ultra and other rapid diagnostic assays for detecting tuberculosis in pulmonary and extra pulmonary specimens. Sci Rep 9:16587CrossRef

15.

Perez-Risco D, Rodriguez-Temporal D, Valledor-Sanchez I, Alcaide F (2018) Evaluation of the Xpert MTB/RIF Ultra assay for direct detection of Mycobacterium tuberculosis complex in smear-negative extrapulmonary samples. J Clin Microbiol 56(9):e00659–e00618CrossRef

16.

Wu X, Tan G, Gao R, Yao L, Bi D, Guo Y, Yu F, Fan L (2019) Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. Int J Infect Dis 81:91–96CrossRef

17.

Hodille E, Maisson A, Charlet L, Bauduin C, Genestet C, Fredenucci I, Rasigade JP, Lina G, Dumitrescu O (2019) Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis on smear-negative respiratory samples in a French centre. Eur J Clin Microbiol Infect Dis 38:601–605CrossRef

18.

Piersimoni C, Gherardi G, Gracciotti N, Pocognoli A (2019) Comparative evaluation of Xpert MTB/RIF and the new Xpert MTB/RIF ultra with respiratory and extra-pulmonary specimens for tuberculosis case detection in a low incidence setting. J Clin Tuberc Other Mycobact Dis 15:100094CrossRef

19.

Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, Oelfese S, Calligaro G, Warren R, Dheda KJ (2018) False-positive Xpert MTB/RIF results in retested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. Clin Microbiol 56(3)

20.

Kendall EA, Schumacher SG, Denkinger CM, Dowdy DW (2017) Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: a modeling study. PLoS Med 14(12):e1002472CrossRef

21.

Ocheretina O, Byrt E, Mabou MM, Royal-Mardi G, Merveille YM, Rouzier V, Fitzgerald DW, Pape JW (2016) False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagn Microbiol Infect Dis 85:53–55CrossRef

22.

Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA (2012) An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 74:207–209CrossRef

Titel: Evaluation of Xpert MTB/RIF Ultra assay for rapid diagnosis of pulmonary and extra-pulmonary tuberculosis in an Italian center
verfasst von: Melissa Menichini
Nicoletta Lari
Antonella Lupetti
Laura Rindi
Publikationsdatum: 31.03.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 8/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-020-03867-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Evaluation of Xpert MTB/RIF Ultra assay for rapid diagnosis of pulmonary and extra-pulmonary tuberculosis in an Italian center

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Performance and ease of use of a molecular point-of-care test for influenza A/B and RSV in patients presenting to primary care

Association between the rate of third generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae and antibiotic consumption based on 143 Chinese tertiary hospitals data in 2014

Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2

Misidentification of Cutibacterium namnetense as Cutibacterium acnes among clinical isolates by MALDI-TOF VitekMS: usefulness of gyrB sequencing and new player in bone infections

In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017–2018

Implementation of the WASPLab™ and first year achievements within a university hospital

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin